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Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the
immunological destruction of intralobular bile ducts and serum anti-mitochondrial antibodies
(AMA). Based upon previous work of oral tolerance and autoimmunity, we hypothesized that feeding
the mitochondrial autoantigens of PBC would alter the clinical course and the level of
antimitochondrial antibodies. The bovine pyruvate dehydrogenase complex (PDC) was purified and
5 mg fed in gelatin capsules to 6 patients with early stage PBC for 6 months. Antimitochondrial
antibodies and liver biochemistries were measured at every 3 months for 12 months. The clinical trial
was completed for all patients except for 1 who showed deterioration of pre-existing skin rash during
treatment, which disappeared within 2 weeks after treatment was discontinued. However, after 1 year,
neither the titers of AMAs nor liver biochemistries were significantly changed by this treatment. This is
the first trial to test the efficacy of oral tolerance induction in PBC. However, the data, which limited in
scope, did not demonstrate efficacy and further highlights the difficulties in showing continuing
evidence of tolerance induction in autoimmunity.
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INTRODUCTION
The current treatment of primary biliary cirrhosis (PBC) is
less than fully satisfactory. In spite of the disease’s
autoimmune nature, most immunosuppressive agents,
including corticosteroids (Mitchison et al., 1989),
cyclosporin (Wiesner et al., 1990; Lombard et al.,
1993), azathioprine (Heathcote et al., 1976), and
methotrexate (Kaplan and Knox, 1991) fail to show
satisfactory clinical benefit. Ursodeoxycholic acid
(UDCA) is a safe and effective medication for most
patients and currently is the therapy of choice for patients
with PBC (Lindor et al., 1994). Treatment with UDCA
leads to not only biochemical and symptomatic improve-
ment but also reduces the risk of developing varices and
improves survival free of liver transplantation (Lindor
et al., 1996; 1997; Poupon et al., 1997). However, up to
two thirds of patients with PBC have abnormal liver tests
despite UDCA treatment (Angulo et al., 1999). Several
combination trials of UDCA with other agents, such as
methotrexate (Lindor et al., 1995), budesonide (Angulo
et al., 2000a), and silymarin (Angulo et al., 2000b), have
not resulted in evidence of benefit from these agents when
added to UDCA.
PBC is characteristically associated with various
autoimmune diseases and findings. One of the most
common findings is positivity for serum anti-mitochon-
drial antibodies (AMA). In the late 1980s, the molecular
targets of AMA were identified (Gershwin et al., 1987)
and promoted progress in understanding the pathophysio-
logy of PBC. These antigens are molecules of the
2-oxoacid dehydrogenase complex located on the
mammalian inner mitochondrial membrane, especially
the E2 component of these enzymes (Van de Water et al.,
1988; Yeaman et al., 1988). The enzyme complex
includes pyruvate dehydrogenase complex (PDC), the
branched chain a-ketoacid dehydrogenase complex
(BCKD), and the oxoglutarate dehydrogenase complex
(OGDC), E1, E2 and E3 (Yeaman, 1989). Among these
molecular targets, AMA are most commonly directed to
the E2 component of PDC (Leung et al., 1992).
Oral tolerance is a potentially therapeutic form of
immunological modulation and this approach of tolerance
induction in autoimmune disease was first reported in
experimental arthritis by oral administration of collagen
type 2 (Nagler-Anderson et al., 1986; Thompson and
Staines, 1986). These reports encouraged attempts to test
whether oral tolerance to the disease-specific autoantigens
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was effective in other experimental autoimmune models
for myasthenia gravis (Wang et al., 1993), thyroiditis
(Peterson and Braley-Mullen, 1995), encephalomyelitis
(Bitar and Whitacre, 1988), and uveoretinitis (Nussenblatt
et al., 1990). There are also encouraging clinical data
showing efficacy of oral tolerance in multiple sclerosis
(Weiner et al., 1993) and rheumatoid arthritis (Trentham
et al., 1993). These previous reports encouraged us to test
our hypothesis by attempting to induce oral tolerance with
the major autoantigens in PBC and PDC-E2.
MATERIALS AND METHODS
Subjects
Six patients with PBC were enrolled. The diagnosis of
PBC was established based on the following criteria: (1)
chronic cholestatic liver disease of at least 6 months’
duration; (2) serum alkaline phosphatase level at least one
and half times the upper limits of normal; (3) positive
antimitochondrial antibody ($1:20 or $1.0 Units); (4)
ultrasound, computed tomography (CT), or cholangio-
graphy of the biliary tree which excluded biliary
obstruction; (5) recent liver biopsy (available for review)
compatible with the diagnosis of PBC and showing stage 1
or 2 disease. Patients were excluded for the following
criteria: (1) pregnancy; (2) anticipated need for transplan-
tation in 1-year with less that 80% 1-year survival without
liver transplantation as determined by the Mayo score; (3)
other serious coexisting complications such as advanced
malignancy or severe cardiopulmonary disease which
would be expected to limit life expectancy to less than
three years; (4) treatment with UDCA, methotrexate,
corticosteroids, azathioprine, chlorambucil, cyclosporin,
budesonide, d-penicillamine, or colchicine, in the
preceding 3 months; (5) age less than 18 years of age or
greater than 70 years of age; (6) findings highly suggestive
of liver diseases of other etiology such as chronic
alcoholic liver disease, chronic hepatitis B or C infection,
autoimmune hepatitis, or sclerosing cholangitis; (7)
patients unable to provide informed consent. The study
was approved by the Mayo Institutional Review Board,
and all patients gave informed consent for participation.
Experimental Design
Six patients who met the criteria mentioned above were
enrolled in the study. Before study entry, a complete
medical history and physical examination were per-
formed. The study duration was 12 months; for the first
6 months, each patient took daily study medication unless
any adverse effects were reported; for the subsequent
6 months they were followed without any medication
for PBC. Blood samples were obtained at baseline, and
repeated at 3-month interval during the study duration.
To test if these study medications induce oral tolerance,
we measured autoantibodies including anti-PDC-E2,
anti-BCKD-E2, and anti-OGDC-E2. We also measured
liver biochemistries including serum alkaline phosphatase,
serum aspartate aminotransferase, total bilirubin, and
albumin to test if any improvement in these data were
induced by oral administration of PDC.
Material
PDC was isolated from beef heart using differential
centrifugation. Fresh USDA inspected beef heart was
obtained from a campus slaughterhouse and stored on ice
in clean plastic bags. The beef heart was diced into small
cubes and homogenized (1:2 w/w) in sterile 0.5 M sorbitol,
0.3 M sucrose, 0.1 mM EDTA and 50 mm Sodium
phosphate at pH 7.4. Care was taken to keep the beef
heart chilled. All materials including blender, knife, and
centrifuge tubes used in this process were purchased
exclusively for this project. The area used for preparation
was cleaned thoroughly and lined with new clean,
absorbent paper. The homogenate was centrifuged at
250g for 10 min, at 48C. After filtering the supernatant
through 4 layers of cheesecloth, this centrifugation was
repeated to obtain clear supernatant. The clarified
supernatant was decanted and centrifuged at 8000g for
10 min, at 48C. The pellet was resuspended in chilled
sorbitol buffer and respun at 8000g for 10 min. at 48C.
This step was then repeated. The mitochondria enriched
pellet was resuspended in 0.02 M potassium phosphate,
pH 6.5 to form a concentrated slurry. A 10 ml of this slurry
was placed in a clean, chilled French press cell (which had
been washed thoroughly and bathed in 70% ETOH for
sterilization). The mitochondria were disrupted using
13,000 psi and the eluate was collected on ice. The
membranes were removed by centrifugation at 20,000g
for 30 min. at 48C. The supernatant was collected and
immediately frozen at 2208C. This solution was dialyzed
against distilled water at 48C and lyophylized. Protein
content of the lyophylized material was measured using
BioRad one step reagent and 10mg loaded on 10% SDS
page gel, transferred, and probed with anti-PDC-E2
(4Cb3) to verify the presence and integrity of PDC-E2.
The final product contains enriched PDC, and includes
other mitochondrial proteins such as BCKD and OGDC.
Study Medication
The amount of PDC in the diet is estimated as about
0.0001–0.001% of total protein. In order to induce oral
tolerance, we administered 5 mg PDC per day, which is
10–100 times more than the estimated amount in the
regular diet. PDC was administered as a single gelatin
capsule, taken once a night at least 2 h after the last meal,
and continued for the first 6 months. For the subsequent
6 months, patients were tested every 3 months. During the
12-month study duration, no other medications for PBC
such as UDCA were allowed. Patients receiving other
treatment for PBC had been discontinued from those
treatments at least 3 months before their enrolment.
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Autoantibody Analysis
Serum autoantibodies against PDC-E2, BCKD-E2, and
OGDC-E2, were analyzed by a standard ELISAwith serial
two-fold dilutions of test sera, up to an 8 £ 1026 dilution.
One hundred microliter aliquot of patient serum mixed
with 1% BSA/PBS was placed in each well of a PDC-E2-
coated microtiter plate for 2 h at 378C to bind to the plates.
After binding, the plates were washed twice and incubated
with peroxidase-conjugated, affinity-purified, polyvalent
goat antihuman IgG. After washing, the plates were
exposed to ABTS (2-azino-bis-thiosulfonate) substrate
and then read at OD414 on a Multiscan machine (Victor 2
plate reader, Perkin Elmer, Boston, MA). The intra-assay
variance for these analyses was between 0.05 and 0.082
standard error of the mean (SEM), while the inter-assay
variance ranged between 0.06 and 1.1 SEM. A positive
value was calculated as three standard deviation above the
mean of the normal controls.
Statistical Analysis
Results were expressed as mean values ^ SEM: The
Wilcoxon signed ranks test was used to compare baseline
vs. 6 and 12 month values of autoantibodies and liver
biochemistries.
RESULTS
The clinical characteristics of the 6 enrolled patients at
entry are summarized in Table I. All patients were female
and the mean age was 51 ^ 3 years (range 42–63).
The mean duration from the first diagnosis made by
liver biopsy to the study entry was 11 ^ 3 months
(range 0.5 – 19). All 6 patients were positive for
anti-mitochondrial antibody. Histologic stage by liver
biopsy was stage 1 in 2, and stage 2 in 4 patients. One
patient who presented with a slight rash at entry
discontinued the study medication on the 9th day since
skin lesions deteriorated after the study medication was
begun; the skin lesions improved within 2 weeks after the
medication was discontinued. The remaining patients
completed 6 months of study medication and the sub-
sequent 6 months of observation. There were no adverse
effects reported except for patient number 5 who noticed a
mild deterioration of pre-existing general lymphadeno-
pathy and Raynaud’s phenomenon while receiving the
study medication. These manifestations improved to the
pre-study level after 6 months of medication.
The values at baseline for liver biochemistries and
autoantibodies are shown in Table II. As shown in the
table, serum ALP was above two times the upper limit of
normal range for all patients and over five times for 1
patient. Serum AST was below two times the upper limit
of normal range for all patients except for the same
patient. Serum total bilirubin and albumin were normal for
all patients. Autoantibodies directed to BCKD-E2,
OGDC-E2, and PDC-E2 were positive for all patients
with various levels among patients as shown, except for 1
patient whose data was not available.
Immunological data were available for 4 of 5 patients.
At 6 months, none of the titers of anti BCKD-E2, OGDC-
E2, and PDC-E2 antibodies differed from the baseline
values ( p ¼ 0:69; 0.61, and 0.86, respectively). Likewise,
at 12 months none of the titers of anti BCKD-E2, OGDC-
E2, and PDC-E2 antibodies were different from baseline
( p ¼ 0:30; 0.57, and 0.45, respectively). With respect to
individual data, the titers of anti-OGDC-E2 and PDC-E2
at 6 months showed an increase for patient No. 3 (Fig. 1).
At 12 months, the titers of anti OGDC-E2 and PDC-E2
TABLE I Clinical characteristics of enrolled patients at entry
Age (year) Gender Duration from Dx (months) Serum AMA Histologic stage
Patient 1 51 F 19 1:80 2
Patient 2 63 F 9 1:80 2
Patient 3 42 F 18 1:320 1
Patient 4 44 F 15 1:20480 2
Patient 5 48 F 0.5 1:80 1
Patient 6 58 F 3 2.6* 2
*Measured by ELISA, Level .1.0 is considered positive.
TABLE II The immunological data and liver biochemistries of patients at entry
Liver biochemistry Autoantibody ( £ 1000)
ALP (U/l) AST (U/l) Total bilirubin (mg/dl) Albumin (g/dl) BC-E2 (O.D.) OG-E2 (O.D.) PDC-E2 (O.D.)
Patient 1 495 56 1.3 4.4 0.124 0.127 0.03
Patient 2 467 38 0.4 3.8 0.132 0.059 0.001
Patient 3 593 32 0.8 3.9 0.053 0.029 0.365
Patient 4 1238 103 0.7 4.2 – – –
Patient 5 466 31 0.4 4.2 0.098 0.131 0.293
Mean ^ SD 652 ^ 148 52 ^ 14 0.7 ^ 0.2 4.1 ^ 0.1 0.102 ^ 0.018 0.087 ^ 0.025 0.172 ^ 0.092
Normal range 81–213 12–31 0.1–1.1 3.5–5.0
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antibody showed decreases for patients No. 1 and No. 5,
respectively (Fig. 1). In contrast, the titers of anti-OGDC-
E2 and PDC-E2 showed increases for patients No. 3,
No. 2 and No. 3, respectively (Fig. 1). There was no
consistency among the antibodies in terms of individual
responses.
With respect to liver biochemistries, serum ALP, AST,
total bilirubin, and albumin at 6-month were not different
from baseline ( p ¼ 0:94; 0.90, 0.68, and 0.13, respect-
ively). The values of serum ALP, AST, total bilirubin, and
albumin at 12-month were also not different from the
values at baseline ( p ¼ 0:99; 0.99, 0.96, and 0.16,
respectively). No apparent improvement or deterioration
was seen in terms of liver biochemistries for any of the
patients during the study duration. Individual values were
plotted in Fig. 2.
DISCUSSION
Autoantibodies reactive to PDC-E2 are the most prevalent
and disease-specific findings and are present in the serum
of 95% of patients with PBC (Yeaman et al., 1988).
However, the role of AMA in the pathogenesis is not fully
understood. There are lines of evidence supporting a
pathophysiological significance of AMA. Immunohisto-
chemical findings showing that the antibody-antigen
complexes are located on the apical portion of the bile
duct epithelial cells (Nakanuma et al., 1995; Tsuneyama
et al., 1995; Leung et al., 1997) suggest that AMA are not
epiphenomenon of the disease but may play a significant
role in the pathogenesis. Furthermore, mice sensitized
intraperitoneally or subcutaneously with bovine PDC
developed AMA and autoimmune cholangitis (Jones et al.,
2000). T cell and B cell reactivity to PDC-E2 in the early
stage of the disease also support the idea that PDC-E2 has
a significant role in the pathogenesis of PBC (Yeaman
et al., 1988; Jones et al., 1995). This supportive evidence
led us to hypothesize that immunological modulation in
the early stage of the disease, designed to eliminate the
titer of AMA, may improve the clinical course and
hopefully provide a medication-free life to the patients.
In this trial, oral administration of bovine PDC was
tested as a means to induce oral tolerance in 6 patients
with early stage PBC, and to determine what, if any,
clinical improvement was manifest by the induction of
oral tolerance. After 6-month of oral antigen adminis-
tration, we did not detect any encouraging changes in the
titers of AMA. We also did not find any improvement in
liver biochemistries. During the subsequent 6 months, no
apparent changes were noted, either in the titers of AMA
or in liver biochemistries. The results of this trial were thus
discouraging.
In the early phase of this study, 1 of 6 patients had to
discontinue study medication because of the deterioration
in a pre-existing skin rash after the medication was begun.
This lesion disappeared within 2 weeks after stopping
medication. Another patient, who presented with lymph-
adenopathy and Raynaud’s phenomenon at entry, noticed
mild deterioration of these manifestations during the
administration of study medication and improvement to
the pre-existed level after completing 6 months of
FIGURE 1 Anti-mitochondrial antibodies to three mitochondrial antigens, BCKD, OGDC, and PDC in patients before and after medication.
(a) Anti-mitochondrial antibody to BCKD. (b) Anti-mitochondrial antibody to OGDC. (c) Anti-mitochondrial antibody to PDC. The horizontal axis of
each chart is the time interval of 12 months study duration. The vertical axis is the titer of each antibody ( £ 1000, O.D.). The dotted line with open
diamonds represents patient No. 1. The solid line with closed squares represents patient No. 2. The dotted line with stars represents patient No. 3. The
solid line with closed triangles represents patient No. 5.
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medication. It is not certain whether there was any causal
relationship between this medication and these manifes-
tations. Otherwise, the medication was tolerable without
any reports of severe adverse effect during the duration of
the study. Many histopathological and immunological
findings suggest an important role of cellular immunity in
the pathogenesis of PBC (Jones et al., 1995; Martinez
et al., 1995; Ohmoto et al., 1997). Considering the
complexity of the immunological mechanisms in PBC, we
may need to evaluate the change of autoimmunity from
different perspectives to confirm whether oral tolerance
was induced, such as testing mucosal T cells and anti-
inflammatory cytokines in addition to peripheral T cell
profiles and autoantibodies.
In this study, we adopted several humoral immunologi-
cal markers to evaluate the induction of oral tolerance. It is
interesting that patient No. 5, who had the shortest interval
from initial diagnosis, showed the greatest decrease in
autoantibody titers during the study. Moreover, plasma
cells producing autoantibodies are long-lived and there-
fore, a change in autoantibody titers may occur slowly
over time.
With respect to liver biochemistries, we could not see
any improvement during the study duration. Regardless of
whether oral tolerance was successfully induced or not, it
is obvious that the current medication was not clinically
effective. Even in the patients with a slight decrease in
AMA titers during the study, we could not see any response
in the liver biochemistries. Whether oral tolerance was
successfully induced, or whether any humoral response
seen during this study was not enough to drive abnormal
autoimmunity to normal, cannot be answered by this study.
There is also the question of whether some patients with
autoimmune disease are incapable of generating tolerance
to orally administered antigens. Also it is still unclear
whether the induction of oral tolerance is beneficial in the
treatment of patients with PBC.
Despite the data in this study, the induction of oral
tolerance could be a novel, safe, and attractive therapeutic
concept in PBC. Oral tolerance therapy has several
benefits including rare adverse effects, easy application,
and no requirement for long-term medication. Considering
that most current treatments of PBC require lifelong
medication, it would be of great benefit to the patients if
we could provide a medication-free or less medicated life.
This approach has been tried in several other autoimmune
diseases such as multiple sclerosis, allergic uveitis,
rheumatoid arthritis, and myasthenia gravis and has
occasionally shown encouraging clinical data especially in
rheumatoid arthritis (Trentham et al., 1993) and multiple
sclerosis (Weiner et al., 1993). However, there are still
challenges in the realization of oral tolerance therapy in
human autoimmune disease, which include determination
of the optimal dosage, molecular configuration of the
antigen, delivery system, and possible variance derived
from individual backgrounds such as age, gender, genetic
predisposition, and also gut flora.
Different amounts of antigen induce different mechan-
isms of immune tolerance. Low doses of oral antigen
induce transferable suppressor T cell mediated tolerance
(Chen et al., 1994), and in contrast, high dose oral antigen
induces clonal energy/deletion (Whitacre et al., 1991;
Chen et al., 1995). We adopted a high dose of oral antigen
administration in this study because it seems to be more
FIGURE 2 Serum alkaline phosphatase, aspartate aminotransferase, total bilirubin, and albumin in patients before and after medication. (a) Alkaline
phosphatase as U/l (normal range: 81–213 U/l). (b) Aspartate aminotransferase as U/l (normal range: 12–31 U/l). (c) Total bilirubin as mg/dl (normal
range: 0.1–1.1 mg/dl). (d) Albumin as g/dl (normal range: 3.5–5.0 g/dl). The horizontal axis of each chart is the time interval of 12 months study
duration. The dotted line with open diamonds represents patient No. 1. The solid line with closed squares represents patient No. 2. The dotted line with
stars represents patient No. 3. The solid line with open squares represents patient No. 4. The solid line with closed triangles represents patient No. 5.
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suitable for the long-term maintenance of the orally
tolerant state. We administered 5 mg of PDC during a
fasting period. Although the amount we used was 10–100
times more than the estimated amount in regular diets, the
ingested protein is labile to degradation during gastro-
intestinal transit by acid and proteases, such as trypsin,
even during the fasting period and may be insufficient for
inducing oral tolerance. We may need to consider antigen
feeding in combination with a trypsin inhibitor and/or
sodium bicarbonate in future trials, which has proved
effective in the field of experimental encephalomyelitis
(Whitacre et al., 1996).
The gut immune system responds differentially to
differences in molecular complexity and small peptide
sequences. In the studies of experimental autoimmune
myasthenia gravis, the oral administration of Torpedo
AchR (nicotinic acetylcholine receptor), one of the
xenogeneic and highly immunogenic autoantigens, during
an acute phase showed induction of autoantibodies and an
increase in the autoantibody titers to self muscle AchR
(Drachman et al., 1996; Shi et al., 1998). In contrast, the
recombinant fragment of human AchR alpha-subunit,
which is a syngeneic, modified, less immunogenic
autoantigen, showed active suppression via Th2/Th3-
secreted regulatory cytokines and induced tolerance when
it was orally administered in experimental autoimmune
myasthenia gravis (Im et al., 1999). We used a bovine
extract containing intact PDC, and some BCKD and
OGDC. Animal studies have shown that intact bovine
PDC with multi-subunit quartenary structure, but not the
monomeric recombinant PDC-E2 inner lipoyl domain,
could cause an immunological response and produce
AMA (Jones et al., 1999). Considering the results from
this previous report, intact bovine PDC may have high
immunogenicity in humans compared to monomeric
recombinant PDC-E2, despite high homology of PDC
molecules among species. This may provide a partial
explanation about the increase in the titers of autoanti-
bodies for some patients, and possible deterioration of
pre-existing manifestations seen in 2 patients during
medication administration. Given the effect of molecular
differences on tolerance induction in experimental
myasthenia gravis, and the breakdown of tolerance in
experimental autoimmune cholangitis, using monomeric
PDC-E2 may be another option for inducing higher oral
tolerance.
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